Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

Iova stock jumps 31% amid FDA setback for rival, short squeeze buzz, and rising momentum for Amtagvi melanoma therapy.

Leveraging Pokémon Go's extensive data, Niantic Spatial is set to redefine digital mapping with more accurate visual ...

Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the ...

Here are 18 downstream projects across various sectors, with Danantara expected to serve as the funding manager.

Replimune stock was down 76.88% in pre-market trading on Tuesday, following a 1.94% rally yesterday. The company’s shares ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ("Replimune or the "Company") (NASDAQ: REPL).

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. A visit to the chiropractor can provide many health benefits.

The National Nutrition Agency (BGN) and the Poverty Alleviation Acceleration Agency (BP Taskin) have agreed to work together to empower poor communities by ...

Kennedy Jr. sued him in his capacity as HHS secretary for not establishing a task force to promote the development of safer ...